title: Protective effect of polydatin against lipopolysaccharide-induced myocardial injury.
abstract: OBJECTIVE
  To observe the effect of lipopolysaccharide (LPS) on actin cytoskeleton of rat cardiac myocytes and the intervention effect of polydatin against this effect.
  
  
  METHODS
  Rat cardiac myocytes were isolated from newborn SD rats (3 days old) and cultured in vitro, which were then divided into control group (treated with D-Hank's solution for 30 min), polydatin group (with 0.2 mmol/L polydatin treatment for 10 min), LPS group (with 100 ng/ml LPS stimulation for 30 min), and LPS/polydatin group (with 100 ng/ml LPS stimulation for 30 min followed by incubation with 0.2 mmol/L polydatin for 10 min). When the treatments were completed, the cells were analyzed for myocardial F-actin by immunofluorescent staining.
  
  
  RESULTS
  In the control group, F-actin was localized in the cortex of cardiac myocytes and the cells were filled with F-actin organized into reticular structures. After LPS stimulation, the staining for F-actin was faint or even invisible in the cortex, with the formation of stress fibers observed in the cells, which disappeared upon the 10-min polydatin treatment and the F-actin resumed normal arrangement. No obvious difference was found between the control and polydatin groups.
  
  
  CONCLUSIONS
  LPS may directly induce stress fiber formation, therefore cause damages to rat cardiac myocytes, which can be reverted by polydatin through the mechanism of participating in the F-actin organization.
authors.affiliation: Key Laboratory for Shock and Microcirculation of PLA, First Military Medical University, Guangzhou 510515, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Zhao
authors.forename: Hai-xiao
authors.initials: HX
authors.lastname: Huang
authors.forename: Chun-hua
authors.initials: CH
authors.lastname: Jin
mesh_terms: D000818:Animals; D009202:Cardiomyopathies / Q000139:chemically induced / Q000517:prevention & control; D004347:Drug Interactions; D005960:Glucosides / Q000494:pharmacology* / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects; D008070:Lipopolysaccharides / Q000494:pharmacology*; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000502:physiology; D020011:Protective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use; D022502:Stress Fibers / Q000187:drug effects*
chemical_list: D005960:Glucosides; D008070:Lipopolysaccharides; D020011:Protective Agents; D013267:Stilbenes; C058229:polydatin